GHRH analog
Sermorelin
Human clinical trialsA short GHRH fragment with a long research history.
Evidence
Human clinical trials
Regulatory status
Not currently marketed as an FDA-approved product.
Class
GHRH analog
What it is
Sermorelin consists of the first 29 amino acids of growth-hormone-releasing hormone, the portion responsible for its activity. It prompts the pituitary to release growth hormone.
What the research shows
- Was previously FDA-approved for diagnosing and treating growth hormone deficiency in children; the branded product was discontinued.
- Human studies in adults are older and relatively small.
Read the published research on PubMed →
Researched for
Sermorelin is not FDA-approved for the uses people commonly discuss. Its safety and effectiveness in people have not been established. Talk to a licensed provider before making any decision.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GHRH analog
Tesamorelin
A growth-hormone-releasing hormone analog with a narrow FDA approval.
FDA-approved drugLong-acting GHRH analogCJC-1295
A modified GHRH analog engineered to last longer in the body.
Early human researchGrowth hormone secretagogueIpamorelin
A selective ghrelin-receptor agonist that stimulates growth hormone release.
Early human research